Nymox Issued U.S. Patent for Saliva Cholesterol Test

MAYWOOD, N.J.--(BUSINESS WIRE)--Oct. 22, 2004--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has received notice of issuance of a new U.S. patent for a unique method and device for using saliva to determine cholesterol levels.

Elevated cholesterol is a well-known major risk factor for heart disease, the leading cause of death in the U.S., and has been implicated as a risk factor for such other diseases as stroke, diabetes, and Alzheimer's disease. The National Heart, Lung and Blood Institute of the NIH recommends routine screening for elevated cholesterol levels. The cholesterol testing market in the U.S. is estimated to be at over 200 million tests a year and is projected to rise as the baby boom generation ages.

“It also augments our existing diagnostic platform technology pipeline.”

"This patent complements our existing patent for the use of statins for the prevention or treatment of Alzheimer's disease and further establishes our proprietary position in a very large and medically important market," said Dr. Paul Averback, CEO of Nymox. "It also augments our existing diagnostic platform technology pipeline."

Using its proprietary test technology, Nymox has developed two products for determining tobacco exposure or use, NicAlert(TM) and TobacAlert(TM). The company also offers AlzheimAlert(TM), a proprietary urine test designed to aid physicians in the diagnosis of Alzheimer's disease, to physicians in the United States through its Clinical Reference Laboratory in Maywood, N.J., at a cost of $295.

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox offers AlzheimAlert(TM), a test to aid in the diagnosis of Alzheimer's disease. The Company is conducting pivotal Phase II clinical trials for NX-1207, a drug for benign prostatic hyperplasia (BPH). The Company markets NicAlert(TM) and TobacAlert(TM) tests for measuring tobacco product exposure. Nymox has a number of drugs in development for Alzheimer's disease, oncology, and infectious disease.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.